Aiosyn

Executive Summary

Aiosyn is a Dutch medical AI company that develops deep learning-based software for digital pathology, addressing critical bottlenecks in cancer and kidney disease diagnostics. Its core product leverages AI-powered mitosis counting to enhance diagnostic accuracy and workflow efficiency in clinical laboratories and biopharma research. Founded in 2020 and headquartered in Nijmegen, Netherlands, the company focuses on modular, seamlessly integrable solutions that fit into existing pathology workflows. The global digital pathology market is growing rapidly, driven by the need for automated, scalable diagnostics and the increasing adoption of AI in healthcare. Aiosyn positions itself to capture value by targeting high-volume, high-impact applications such as tumor grading and kidney biopsy analysis. While the company remains private with undisclosed funding, its technology has the potential to reduce pathologist workload, improve diagnostic consistency, and accelerate drug development through quantitative tissue analysis. Key risks include regulatory hurdles, competition from established players (e.g., PathAI, Paige.AI), and the need for clinical validation in diverse populations. However, Aiosyn's focus on niche, high-need areas and its Dutch innovation ecosystem could provide a competitive edge.

Upcoming Catalysts (preview)

• Q3 2026CE-IVDR certification for kidney disease AI software75% success
• Q4 2026Strategic partnership with a top-10 pharma for oncology drug development60% success
• Q2 2027FDA 510(k) clearance for breast cancer mitosis counting tool50% success